Research Focus

Dr. Van der Jeught’s laboratory aims at discovering pathways and developing tools to improve cancer immunotherapy treatments. He pioneered the use of mRNA encoding soluble factors to successfully modify the suppressive tumor microenvironment, leading to enhanced anti-tumor immune responses. Additionally, he demonstrated that strong systemic immune responses can be generated in a safe way using lipid-based mRNA nanoparticles. Recently, he discovered ST2 as checkpoint target for colorectal cancer immunotherapy and aims to expand and improve checkpoint immunotherapy.